13 years of DHG Pharma's position in the Top 50 Best Listed Companies in Vietnam

DHG Pharma continues to affirm its pioneering position in the pharmaceutical industry, with the 13th consecutive year being honored by Forbes as “Top 50 Best Listed Companies in Vietnam”.

On the eve of its 51st birthday, DHG Pharma continues to mark its milestone by entering the "Top 50 Best Listed Companies in Vietnam 2025" voted by Forbes Vietnam. Forbes evaluates businesses based on business results - financial indicators - the ability to maintain sustainable profits.

"Winning this title for 13 consecutive years is not only an affirmation of the leading position in the pharmaceutical industry, but also a meaningful gift for the DHG Pharma team - the people who are together continuing the journey of more than half a century of serving public health ," emphasized General Director Toshiyuki Ishii of DHG Pharma.

DHG Pharma received the title of "Top 50 Best Listed Companies in Vietnam 2025" on August 21, 2025.

Steady growth on strong financial foundation

Forbes' quantitative assessments of "financial health" acknowledge DHG Pharma's methodical development strategy in a volatile market. At the same time, the qualitative criteria demonstrate the trust of investors and consumers, further strengthening DHG Pharma's reputation in the domestic business community.

More specifically, DHG Pharma has continuously achieved steady growth in revenue and profit. DHG Pharma is among the listed companies with medium capitalization and healthy financial indicators, highly appreciated by investors.

Among the 3 pharmaceutical companies in the Forbes Top 50 2025, DHG Pharma continues to hold the leading position. The company is highly ranked for its long-standing prestigious brand, holding the leading market share in the non-prescription drug segment. The multi-channel distribution network has now expanded to 30,000 traditional pharmacies (OTC), 3,546 stores belonging to 5 major pharmacy chains (MTC), 3,200 hospitals and clinics (ETC) nationwide, and export markets to 20 countries.

DHG Pharma is highly ranked for its long-standing reputation as a prestigious brand, holding the leading market share in the non-prescription drug segment.

Owning two modern factories meeting JAPAN GMP (Japan) and EU GMP (Europe) standards, DHG Pharma is currently considered a model of standardization, creating momentum for the pharmaceutical industry to upgrade its production chain and develop in the direction of "domestic drugs with international quality". Currently, only 10% of the entire industry's factories meet similar high standards, while the remaining 90% meet WHO GMP standards by the end of 2024. Thanks to the long-term participation of strategic shareholder Taisho (Japan), the enterprise also standardizes transparent governance and increases international cooperation advantages.

The Forbes Top 50 2025 ranking also measures brand value associated with social trust. DHG Pharma is continuously trusted by consumers through awards: Top 10 Prestigious Pharmaceutical Enterprises, High Quality Vietnamese Goods... In addition, the company actively contributes to the community, taking care of people's health in many regions, through more than 100 programs each year.

Long-term development orientation to maintain leading position

The Forbes Top 50 2025 list was announced at a time when DHG Pharma is promoting its long-term development strategy of "growth pivot" - focusing on product restructuring and cost optimization across the entire pharmaceutical value chain.

General Director Toshiyuki Ishii said that DHG Pharma has accelerated investment in technology and international standard production in recent times. In the near future, the company will expand production capacity, complete EU-GMP standards for new production lines, as well as apply digital transformation and automation to improve productivity and quality control.

At the same time, DHG Pharma promotes the development of new products and transfers the production technology of famous products of Taisho Group (Japan), in order to enhance domestic competitiveness with a differentiated product system. In 2024, the company was granted registration numbers for 23 new products and deployed the production of 13 more products.

Mr. Toshiyuki Ishii - General Director of DHG Pharma shared that DHG Pharma will always uphold the mission 'For a healthier and more beautiful life', to continue to be a symbol of peace of mind and innovation in the pharmaceutical industry.

In addition to traditional distribution channels, the company is building e-commerce channels. The international market is also being expanded with a selective export orientation to potential markets, focusing on penetrating deeply into the ASEAN market.

In particular, DHG Pharma is a pioneer in pursuing the long-term ESG (Environment, Society, Governance) Sustainable Development strategy. The company has published a GRI-standard Sustainability Report since 2020, anticipating the "green investment" trend, which is still new in the pharmaceutical industry.

"Forbes named DHG Pharma not only because of today's business results, but also because of the solid core values ​​that have been cultivated over the past half century and the orientation for sustainable development in the future. We will always uphold the mission 'For a healthier and more beautiful life', to continue to be a symbol of peace of mind and innovation in the pharmaceutical industry," affirmed Mr. Toshiyuki Ishii.

Source: https://phunuvietnam.vn/13-nam-vung-vi-the-top-50-cong-ty-niem-yet-tot-nhat-viet-nam-cua-dhg-pharma-20250825094308235.htm